ArticleFrontiers in neurology2025
Tubridge flow diverter for the treatment of dissecting aneurysms in the middle cerebral artery.
Article in Frontiers in neurology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Middle cerebral artery dissecting aneurysms: A systematic review of presentation, etiology, and prognosis.Surgical neurology international · 2026Review
- Flow diverter treatment for MCA M1 aneurysms: clinical outcomes and predictors of occlusion.Frontiers in neurologyArticle
- Preliminary experience of Tubridge Plus flow diverter in the treatment of intracranial aneurysms.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The Tubridge flow diverter (TFD) has become a widely used device for reconstructing parent vessels and sealing complicated aneurysms in China. However, its application to managing distal small to medium-sized dissecting aneurysms has not been extensively investigated. This study aimed to evaluate the safety and effectiveness of the TFD and the factors affecting healing in patients with dissecting aneurysms in the middle cerebral artery (MCA). Methods: Patients with dissecting aneurysms in the MCA who were treated with the TFD from 2019 to 2023 were included. According to the O'Kelly-Marotta (OKM) scale, OKM grade A was defined as dense embolism, while OKM grades B to D were defined as non-dense embolism in this study. Clinical information, the degree of aneurysm occlusion, and clinical outcomes were retrospectively analyzed. Results: A total of 25 patients with 25 MCA dissecting aneurysms were identified. The average age was 52.4 years (age range 20-76), with 5 patients (20%) experiencing subarachnoid hemorrhage. In total, 12 aneurysms were located in the M1 segment, 11 involved the M2 bifurcation, and two were in the M3 segment or above. The median aneurysm length was 17.3 mm (range 4.2-27), and the average width was 5.4 mm (range 2.3-7.6). A total of 12 cases had one or more branches in the MCA. Furthermore, four cases (16%) showed asymptomatic in-stent stenosis, and five cases (20%) had main branch injuries during the angiographic follow-up. A total of three patients experienced acute ischemic events, and one had not fully recovered during the follow-up. There were no deaths related to procedure complications. According to the single-factor analysis, the patients in the non-dense embolism group during the follow-up had more strong branches before the operation (χ Conclusion: The TFD is a safe and effective flow diverter for distal dissecting MCA aneurysms. The aneurysms with strong branches were associated with a higher rate of non-dense embolism during the follow-up.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.